Search | Clinical Trials Finder

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Hemoglobin SC Disease, Sickle Cell Anemia
Interventions: Recombinant-methionyl human stem cell factor; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: nitric oxide, oxygen; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 9 Years to 22 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Nitric Oxide, INO Pulse - NO Delivery System; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions: Inclacumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Conditions: Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
Interventions: Comprehensive Care Plan; Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 12 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD); Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Anemia Crisis
Interventions: Acetaminophen, Normal saline; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 4 Years to 16 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Newark, New York

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Conditions: Sickle Cell Crisis
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Pain, Sickle Cell Disorder
Interventions: Normal saline, Ketamine; Drug
Lead sponsor: Billy Sin; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Acute Vaso Occlusive Crisis (VOC)
Interventions: L-citrulline, D5 1/2NS; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Jackson, Mississippi

Conditions: Sickle Cell Disease
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions: Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion; Drug
Lead sponsor: Mohsen Saidinejad; Other
Eligibility: 5 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Torrance, California

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Crisis
Interventions: Virtual Reality Goggles; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 6 Years to 21 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions: GMI-1070, Placebo; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 21
States / cities: Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
Interventions: Rivipansel; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 85
States / cities: Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 28 more

Conditions: Sickle Cell Crisis, Sickle Cell Disease
Interventions: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Anumigilimab, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Little Rock, Arkansas • Hollywood, Florida • Bethesda, Maryland + 2 more

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome
Interventions: A-001, Placebo; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 5 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 11 more

Search by objective public record fields.

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Low Dose Ketamine and Acute Pain Crisis

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Virtual Reality as an Adjuvant Therapy for Sickle Cell Vaso-Occlusive Crisis in the Pediatric Emergency Department

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)